WuXi AppTec Co Ltd
SSE:603259

Watchlist Manager
WuXi AppTec Co Ltd Logo
WuXi AppTec Co Ltd
SSE:603259
Watchlist
Price: 55.64 CNY -1.43% Market Closed
Market Cap: 160.7B CNY
Have any thoughts about
WuXi AppTec Co Ltd?
Write Note

WuXi AppTec Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

WuXi AppTec Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
WuXi AppTec Co Ltd
SSE:603259
Total Receivables
¥10.1B
CAGR 3-Years
23%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Receivables
¥2.9B
CAGR 3-Years
26%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Receivables
¥6.8B
CAGR 3-Years
13%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Receivables
¥4.3B
CAGR 3-Years
31%
CAGR 5-Years
31%
CAGR 10-Years
33%
Genscript Biotech Corp
HKEX:1548
Total Receivables
$299.5m
CAGR 3-Years
47%
CAGR 5-Years
43%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Total Receivables
¥985.8m
CAGR 3-Years
177%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi AppTec Co Ltd
Glance View

Market Cap
162B CNY
Industry
Life Sciences Tools & Services

In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.

Intrinsic Value
88.23 CNY
Undervaluation 37%
Intrinsic Value
Price

See Also

What is WuXi AppTec Co Ltd's Total Receivables?
Total Receivables
10.1B CNY

Based on the financial report for Sep 30, 2024, WuXi AppTec Co Ltd's Total Receivables amounts to 10.1B CNY.

What is WuXi AppTec Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
25%

Over the last year, the Total Receivables growth was 12%. The average annual Total Receivables growth rates for WuXi AppTec Co Ltd have been 23% over the past three years , 25% over the past five years .

Back to Top